Hybrid synthetic approach and biological characterization of a branched heterodimer for overcoming prostate cancer heterogeneity
Prostate cancer is the fifth cause of cancer-related death in men over the world (375 000 cases in 2020) 5-year survival rate of 31% at the late stage.[1] Radiolabelled Prostate-Specific Membrane Antigen (PSMA) inhibitors entry in clinical practice for imaging ([ 68 Ga]Ga-PSMA-11) and therapy ([ 177 Lu]Lu-PSMA-617).[2] 80% of prostate cancers show high heterogeneity low expression of PSMA and presence of multiple distinct tumour foci.
Authors
- Sacha Bodin (ORCID: https://orcid.org/0000-0001-7331-8536)
- Santo Previti
- Clément Morgat (ORCID: https://orcid.org/0000-0002-9432-9223)
- Florine Cavelier (ORCID: https://orcid.org/0000-0001-5308-6416)
- Emmanuelle Rémond (ORCID: https://orcid.org/0000-0002-3201-4365)
Institutions
- University of Messina (IT)
- Centre National de la Recherche Scientifique (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Institut de Neurosciences Cognitives et Intégratives d’Aquitaine (FR)
- Institut des Biomolécules Max Mousseron (FR)
Publication Details
- Published
- 2024-09-20
- DOI
- https://doi.org/10.17952/37eps.2024.p1128
- Primary Topic
- Advanced Polymer Synthesis and Characterization
- Type
- article
- Field-Weighted Citation Impact
- 0.00